RNAC Relative Valuation - Cartesian Therapeutics Inc - Alpha Spread

Cartesian Therapeutics Inc
NASDAQ:RNAC

Watchlist Manager
Cartesian Therapeutics Inc Logo
Cartesian Therapeutics Inc
NASDAQ:RNAC
Watchlist
Price: 16.54 USD 5.82% Market Closed
Market Cap: 353.6m USD
Have any thoughts about
Cartesian Therapeutics Inc?
Write Note

Relative Value

The Relative Value of one RNAC stock under the Base Case scenario is 9.13 USD. Compared to the current market price of 16.54 USD, Cartesian Therapeutics Inc is Overvalued by 45%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RNAC Relative Value
Base Case
9.13 USD
Overvaluation 45%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
92
vs Industry
39
Median 3Y
13.8
Median 5Y
21.5
Industry
7.7
Forward
7.8
vs History
vs Industry
12
Median 3Y
-2.2
Median 5Y
-20.5
Industry
23.9
Forward
-3.5
vs History
vs Industry
Median 3Y
-17.1
Median 5Y
-18.7
Industry
22.2
vs History
vs Industry
Median 3Y
-14.2
Median 5Y
-17.1
Industry
24
vs History
vs Industry
53
Median 3Y
9.7
Median 5Y
-3.2
Industry
2.5
vs History
92
vs Industry
40
Median 3Y
9.9
Median 5Y
19.2
Industry
7.4
Forward
5.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.5
vs History
vs Industry
29
Median 3Y
-5.3
Median 5Y
-19
Industry
5.1
vs History
vs Industry
28
Median 3Y
-5.2
Median 5Y
-18.8
Industry
4.7
Forward
-4.3
vs History
vs Industry
29
Median 3Y
-15.1
Median 5Y
-16.7
Industry
6.6
vs History
vs Industry
26
Median 3Y
-15
Median 5Y
-16.6
Industry
4.7
vs History
95
vs Industry
57
Median 3Y
22.8
Median 5Y
33.9
Industry
4.7

Multiples Across Competitors

RNAC Competitors Multiples
Cartesian Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Cartesian Therapeutics Inc
NASDAQ:RNAC
353.6m USD 6.5 -1.5 -5.5 -5.4
US
Abbvie Inc
NYSE:ABBV
341.9B USD 6.2 64.6 15.8 24.1
US
Amgen Inc
NASDAQ:AMGN
180.5B USD 5.8 57.7 20.2 36.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
129B USD 9.6 29.8 26.2 29
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.6B USD 12 -252.2 26.8 28.2
US
Gilead Sciences Inc
NASDAQ:GILD
104.5B USD 3.8 99.3 9.4 12
US
Epizyme Inc
F:EPE
94.1B EUR 1 981.8 -505.7 -550.7 -536
AU
CSL Ltd
ASX:CSL
142.3B AUD 6.5 36.7 22.4 28
US
Seagen Inc
F:SGT
39.3B EUR 19.1 -58.5 -63 -56.9
US
Palatin Technologies Inc
LSE:0KF3
38.5B USD 6 513.5 -1 169.6 -1 185.3 -1 173.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
35.4B USD 15.1 -485.3 213.7 328.9
P/E Multiple
Earnings Growth
US
Cartesian Therapeutics Inc
NASDAQ:RNAC
Average P/E: 57.6
Negative Multiple: -1.5
N/A
US
Abbvie Inc
NYSE:ABBV
64.6
406%
US
Amgen Inc
NASDAQ:AMGN
57.7
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.8
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -252.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
99.3
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.7 N/A
AU
CSL Ltd
ASX:CSL
36.7
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 169.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -485.3 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Cartesian Therapeutics Inc
NASDAQ:RNAC
Average EV/EBITDA: 47.8
Negative Multiple: -5.5
N/A
US
Abbvie Inc
NYSE:ABBV
15.8
28%
US
Amgen Inc
NASDAQ:AMGN
20.2
57%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
26.2
47%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
39%
US
Gilead Sciences Inc
NASDAQ:GILD
9.4
10%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -550.7 N/A
AU
CSL Ltd
ASX:CSL
22.4
45%
US
S
Seagen Inc
F:SGT
Negative Multiple: -63 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 185.3 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
213.7
N/A
EV/EBIT Multiple
EBIT Growth
US
Cartesian Therapeutics Inc
NASDAQ:RNAC
Average EV/EBIT: 69.5
Negative Multiple: -5.4
N/A
US
Abbvie Inc
NYSE:ABBV
24.1
86%
US
Amgen Inc
NASDAQ:AMGN
36.6
95%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29
49%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
12
26%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -536 N/A
AU
CSL Ltd
ASX:CSL
28
59%
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.9 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 173.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
328.9
N/A

See Also

Discover More
Back to Top